Shilpa Medicare Shares Surge on Launch of BORUZU in US

Shilpa Medicare Limited, a leading pharmaceutical company, has expanded its global footprint with the launch of BORUZU™ (Bortezomib for Injection 3.5mg/1.4ml) in the United States. Partnering with Amneal Pharmaceuticals, this launch marks a significant step in providing more efficient and accessible oncology treatments. The ready-to-use formulation aims to enhance patient care by reducing preparation time and improving administration convenience.

A Milestone in Oncology Treatment

Shilpa Medicare, in collaboration with its marketing partner Amneal Pharmaceuticals, has introduced BORUZU™, a novel oncology drug designed for both subcutaneous and intravenous administration. Unlike traditional bortezomib formulations that require reconstitution before use, BORUZU™ comes in a ready-to-use form, eliminating complex compounding steps. This advancement is expected to improve operational efficiency in healthcare settings and reduce patient wait times.

BORUZU™ is a proteasome inhibitor used for the treatment of multiple myeloma and mantle cell lymphoma. The drug has received a permanent J-code from the U.S. Centers for Medicare & Medicaid Services (CMS), ensuring streamlined reimbursement for medical providers. The molecule was developed by Shilpa Medicare, while Amneal Pharmaceuticals will handle its manufacturing and commercial distribution in the US market.

Shilpa Medicare’s Vision in the Pharmaceutical Industry

Shilpa Medicare has consistently demonstrated its commitment to innovation by developing advanced pharmaceutical solutions. The company specialises in niche oncology and non-oncology Active Pharmaceutical Ingredients (APIs), peptides, and differentiated dosage forms, including injectables and transdermal patches. With multiple R&D centres and manufacturing facilities, it also provides Contract Development and Manufacturing Organisation (CDMO) services to global pharmaceutical firms.

According to Vishnukant Bhutada, Managing Director of Shilpa Medicare, the launch of BORUZU™ highlights the company’s focus on introducing pharmacy-efficient solutions that enhance compliance and accessibility for patients. This development aligns with Shilpa’s broader mission to improve healthcare by delivering high-quality and innovative pharmaceutical products worldwide.

Shilpa Medicare Share Performance 

As of April 03 2025, at 1:00 PM, Shilpa Medicare share price was trading at ₹679.70, reflecting a surge of 4.88% from its previous closing price. Over the past month, it has surged by 12.60%.

Conclusion

The introduction of BORUZU™ in the US market represents a major achievement for Shilpa Medicare, reinforcing its position as a key player in the oncology pharmaceutical sector. By offering a ready-to-use formulation, the company is enhancing the efficiency of cancer treatment while improving patient experience. This milestone reflects Shilpa Medicare’s ongoing commitment to pharmaceutical excellence and innovation.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.